<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2607222350
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIMPAT 10 mg/ml SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LACOSAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        517.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Italia S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Italia S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Vimpat is and what it is used for</strong></p><p>&nbsp;</p><p><strong>What Vimpat is</strong></p><p>Vimpat contains lacosamide. This belongs to a group of medicines called &ldquo;antiepileptic medicines&rdquo;. These medicines are used to treat epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have been given this medicine to lower the number of fits (seizures) you have.</p><p>&nbsp;</p><p><strong>What Vimpat is used for</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vimpat is used in adults, adolescents and children aged 4&nbsp;years and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is used to treat a certain type of epilepsy characterised by the occurrence of partial-onset seizure with or without secondary generalisation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In this type of epilepsy, fits first affect only one side of your brain. However, these may then spread to larger areas on both sides of your brain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vimpat may be used on its own or with other antiepileptic medicines.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you use Vimpat </strong></p><p><u>&nbsp;</u></p><p><strong>Do not use Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lacosamide, or any of the other ingredients of this medicine (listed in section&nbsp;6). If you are not sure whether you are allergic, please discuss with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a certain type of heart beat problem called second- or third-degree AV block.</p><p>&nbsp;</p><p>Do not use Vimpat if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before using this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before using Vimpat if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have thoughts of harming or killing yourself. A small number of people being treated with antiepileptic medicinal products such as lacosamide have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a heart problem that affects the beat of your heart and you often have a particulary slow, fast or irregular heart beat (such as AV block, atrial fibrillation and atrial flutter).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe heart disease such as heart failure or have had a heart attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are often dizzy or fall over. Vimpat may make you dizzy - this could increase the risk of accidental injury or a fall. This means that you should take care until you are used to the effects of this medicine.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before using Vimpat.</p><p>If you are taking Vimpat and you are experiencing symptoms of abnormal heartbeat (such as slow, rapid or irregular heartbeat, palpitations, shortness of breath, feeling lightheaded, fainting), seek medical advice immediately (see section 4).</p><p>&nbsp;</p><p><strong>Children under 4&nbsp;years</strong></p><p>Vimpat is not recommended for children aged under 4&nbsp;years. This is because we do not yet know whether it will work and whether it is safe for children in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Vimpat</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect your heart - this is because Vimpat can also affect your heart:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat heart problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which can increase the &ldquo;PR interval&rdquo; on a scan of the heart (ECG or electrocardiogram) such as medicines for epilepsy or pain called carbamazepine, lamotrigine or pregabalin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat certain types of irregular heart beat or heart failure.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before using Vimpat.</p><p>&nbsp;</p><p>Also tell your doctor or pharmacist if you are taking any of the following medicines - this is because they may increase or decrease the effect of Vimpat on your body:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fungal infections called fluconazole, itraconazole or ketoconazole;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine for HIV called ritonavir;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for bacterial infections called clarithromycin or rifampicin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a herbal medicine used to treat mild anxiety and depression called St.&nbsp;John&rsquo;s wort.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before using Vimpat.</p><p>&nbsp;</p><p><strong>Vimpat with alcohol</strong></p><p>As a safety precaution do not use Vimpat with alcohol.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p><strong>&nbsp;</strong></p><p>It is not recommended to use Vimpat if you are pregnant or breast feeding, as the effects of Vimpat on pregnancy and the unborn baby or the new-born child are not known. Also, it is not known whether Vimpat passes into breast milk. Seek advice immediately from your doctor if you get pregnant or are planning to become pregnant. They will help you decide if you should use Vimpat or not.</p><p>&nbsp;</p><p>Do not stop treatment without talking to your doctor first as this could increase your fits (seizures). A worsening of your disease can also harm your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive, cycle or use any tools or machines until you know how this medicine affects you. This is because Vimpat may make you feel dizzy or cause blurred vision.</p><p>&nbsp;</p><p><strong>Vimpat contains sodium</strong></p><p>This medicine contains 2.6&nbsp;mmol (or 59.8&nbsp;mg) of sodium in each vial. You need to know this if you are on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to use Vimpat </strong></p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Using Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vimpat can be started by:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taking the medicine by mouth or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by being given as an intravenous infusion (sometimes called an &ldquo;IV infusion&rdquo;) where the medicine is given into your vein by a doctor or nurse. It is given over 15 to 60&nbsp;minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The IV infusion is usually used for a short time when you cannot take the medicine by mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide for how many days you will have infusions. There is experience with twice daily infusions of Vimpat for up to 5&nbsp;days. For longer term treatment Vimpat tablets and syrup are available.</p><p>&nbsp;</p><p>When you change from the infusion to taking the medicine by mouth (or the other way around) the total amount you take each day and how often you take it stays the same.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Vimpat twice each day &ndash; once in the morning and once in the evening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Try to use it at about the same time each day.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>Listed below are the normal recommended doses of Vimpat for different age groups and weights. Your doctor may prescribe a different dose if you have problems with your kidneys or with your liver.</p><p>&nbsp;</p><p><strong>Adolescents</strong><strong> and children weighing 50</strong>&nbsp;<strong>kg or more</strong><strong> and adults</strong></p><p><u>When you use Vimpat on its own</u></p><p>The usual starting dose of Vimpat is 50&nbsp;mg twice a day.</p><p>The treatment with Vimpat may also start with a dose of 100&nbsp;mg of Vimpat twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50&nbsp;mg. This will be until you reach a maintenance dose of between 100&nbsp;mg and 300&nbsp;mg twice a day.</p><p>&nbsp;</p><p><u>When you use Vimpat with other antiepileptic medicines</u></p><p>The usual starting dose of Vimpat is 50&nbsp;mg twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50&nbsp;mg. This will be until you reach a maintenance dose of between 100&nbsp;mg and 200&nbsp;mg twice a day.</p><p>&nbsp;</p><p>If you weigh 50&nbsp;kg or more, your doctor may decide to start Vimpat treatment with a single &ldquo;loading&rdquo; dose of 200&nbsp;mg. You would then start your ongoing maintenance dose 12&nbsp;hours later.</p><p>&nbsp;</p><p><strong>Children and adolescents weighing less than 50</strong>&nbsp;<strong>kg</strong></p><p><u>When you use Vimpat on its own</u></p><p>Your doctor will decide the dose of Vimpat based on your body weight.</p><p>&nbsp;</p><p>The usual starting dose is 1 mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</p><p>Your doctor may then increase your twice daily dose every week by 1 mg (0.1 ml), for each kg of your body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 6&nbsp;mg (0.6 ml) for each kg of body weight, twice a day, for children weighing under 40&nbsp;kg. The maximum maintenance dose is 5&nbsp;mg (0.5&nbsp;ml) for each kg of body weight, twice a day, for children weighing from 40 kg to under 50 kg. Dosing charts are provided below:</p><p>&nbsp;</p><p>Using Vimpat on its own &ndash;<strong> </strong>This is for information only. Your doctor will work out the right dose for you:</p><p>&nbsp;</p><p>To<strong> be used twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 40&nbsp;kg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.6 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>12.5 ml</p></td><td style="vertical-align:top"><p>15 ml</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td><td style="vertical-align:top"><p>15 ml</p></td><td style="vertical-align:top"><p>18 ml</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml</p></td><td style="vertical-align:top"><p>7 ml</p></td><td style="vertical-align:top"><p>10.5 ml</p></td><td style="vertical-align:top"><p>14 ml</p></td><td style="vertical-align:top"><p>17.5 ml</p></td><td style="vertical-align:top"><p>21 ml</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>To be used twice daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 40</strong>&nbsp;<strong>kg to under 50&nbsp;kg</strong>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.5 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td><td style="vertical-align:top"><p>16 ml</p></td><td style="vertical-align:top"><p>20 ml</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>13.5 ml</p></td><td style="vertical-align:top"><p>18 ml</p></td><td style="vertical-align:top"><p>22.5 ml</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>When you use Vimpat with other antiepileptic medicines</u></p><p>Your doctor will decide the dose of Vimpat based on your body weight.</p><p>&nbsp;</p><p>In children from 4&nbsp;years of age with a body weight of under 20&nbsp;kg:</p><ul><li>the usual starting dose is 1&nbsp;mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</li></ul><p>&nbsp;</p><p>Your doctor may then increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml) for each kg of body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 6&nbsp;mg (0.6&nbsp;ml), for each kg of body weight, twice a day. A dosing chart is provided below.</p><p>&nbsp;</p><p>Using Vimpat with other antiepileptic medicines - <strong>Children above 4 years of age weighing less than 20</strong>&nbsp;<strong>kg </strong>&ndash; This is for information only. Your doctor will work out the right dose for you:</p><p>&nbsp;</p><p><strong>To be used twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 20&nbsp;kg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.6 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td></tr></tbody></table><p>&nbsp;</p><p>In children from 4 years of age with a body weight of 20&nbsp;kg to under 30&nbsp;kg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual starting dose is 1 mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml), for each kg of body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 5&nbsp;mg (0.5&nbsp;ml), for each kg of body weight, twice a day. A dosing chart is provided below.</p><p>&nbsp;</p><p>Using Vimpat with other antiepileptic medicines - <strong>Children and adolescents with a body weight of 20 to under 30 kg </strong>- This is for information only. Your doctor will work out the right dose for you:</p><p>&nbsp;</p><p><strong>To be used twice daily</strong> for children and adolescents from 4 years of age <strong>weighing 20</strong>&nbsp;<strong>kg to under 30&nbsp;kg</strong>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.5 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>12.5 ml</p></td></tr></tbody></table><p>&nbsp;</p><p>In children from 4&nbsp;years of age with a body weight of 30 to under 50&nbsp;kg:</p><ul><li>the usual starting dose is 1&nbsp;mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</li></ul><p>&nbsp;</p><p>Your doctor may then increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml) for each kg of body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 4&nbsp;mg (0.4&nbsp;ml), for each kg of body weight, twice a day. A dosing chart is provided below.</p><p>&nbsp;</p><p>Using Vimpat with other antiepileptic medicines - <strong>Children and adolescents with a body weight of 30&nbsp;kg to under 50&nbsp;kg - </strong>This is for information only. Your doctor will work out the right dose for you:</p><p>&nbsp;</p><p><strong>To be used twice daily</strong> for children and adolescents from 4 years of age <strong>weighing 30&nbsp;kg to under 50&nbsp;kg</strong>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.4 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml</p></td><td style="vertical-align:top"><p>7 ml</p></td><td style="vertical-align:top"><p>10.5 ml</p></td><td style="vertical-align:top"><p>14 ml</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td><td style="vertical-align:top"><p>16 ml</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>13.5 ml</p></td><td style="vertical-align:top"><p>18 ml</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>If you stop using Vimpat</strong></p><p>If your doctor decides to stop your treatment with Vimpat, they will decrease the dose step by step. This is to prevent your epilepsy from coming back again or becoming worse.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</strong></p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Nervous system side effects such as dizziness may be higher after a single &ldquo;loading&rdquo; dose.</p><p>&nbsp;</p><p><strong>Talk to your doctor or pharmacist if you get any of the following:</strong></p><p>&nbsp;</p><p><strong>Very common</strong>: may affect more than 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or sick (nausea);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision (diplopia).</p><p>&nbsp;</p><p><strong>Common</strong>: may affect up to 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems in keeping your balance, shaking (tremor), tingling (paresthesia) or muscle spasms, falling easily and getting bruises;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Troubles with your memory, thinking or finding words, confusion;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid and uncontrollable movements of the eyes (nystagmus), blurred vision;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning sensation (vertigo), feeling drunk;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting), dry mouth, constipation, indigestion, excessive gas in the stomach or bowel, diarrhoea;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased feeling or sensitivity, difficulty in articulating words, disturbance in attention;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Noise in the ear such as buzzing, ringing or whistling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability, trouble sleeping, depression;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, tiredness or weakness (asthenia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart rate, palpitations, irregular pulse or other changes in the electrical activity of your heart (conduction disorder);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exaggerated feeling of wellbeing, seeing and/or hearing things which are not there;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction to medicine intake, hives;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show abnormal liver function, liver injury;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts of harming or killing yourself or attempting suicide: tell your doctor straight away;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling angry or agitated;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal thinking or losing touch with reality;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction which causes swelling of the face, throat, hands, feet, ankles, or lower legs;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties in coordinating your movements or walking.</p><p>&nbsp;</p><p><strong>Not known</strong>: frequency cannot be estimated from available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal rapid heartbeat (ventricular tachyarrhythmia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sore throat, high temperature and getting more infections than usual. Blood tests may show a severe decrease in a specific class of white blood cells (agranulocytosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious skin reaction which may include a high temperature and other flu-like symptoms, a rash on the face, extended rash, swollen glands (enlarged lymph nodes). Blood tests may show increased levels of liver enzymes and a type of white blood cell (eosinophilia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens&ndash;Johnson syndrome), and a more severe form causing skin peeling in more than 30&nbsp;% of the body surface (toxic epidermal necrolysis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion.</p><p>&nbsp;</p><p><strong>Additional side effects when given as an intravenous infusion</strong></p><p>There may be local side effects.</p><p>&nbsp;</p><p><strong>Common</strong>: may affect up to 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site pain or discomfort or irritation.</p><p>&nbsp;</p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site redness.</p><p><strong>&nbsp;</strong></p><p><strong>Additional side effects in children </strong></p><p><strong>&nbsp;</strong></p><p><strong>Common: </strong>may affect up to 1 in 10&nbsp;children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Runny nose (nasopharyngitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (pyrexia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat (pharyngitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eating less than usual.</p><p>&nbsp;</p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy or lacking in energy (lethargy).</p><p>&nbsp;</p><p><strong>Not known: </strong>frequency cannot be estimated from available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in behaviour, not acting like themselves.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Vimpat </strong></p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Each vial of Vimpat solution for infusion must be used only once (single use). Any unused solution should be discarded.</p><p>&nbsp;</p><p>Only clear solution free from particles and discoloration should be used.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other information</strong></p><p>&nbsp;</p><p><strong>What Vimpat contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lacosamide.</p><p>1&nbsp;ml Vimpat solution for infusion contains 10&nbsp;mg lacosamide.</p><p>1&nbsp;vial contains 20&nbsp;ml Vimpat solution for infusion equivalent to 200&nbsp;mg lacosamide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium chloride, hydrochloric acid, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Vimpat looks like and contents of the pack
•	Vimpat 10 mg/ml solution for infusion is a clear, colourless solution.
Vimpat solution for infusion is available in packages of 1 vial and 5 vials. Each vial contains 20 ml.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>UCB Pharma S.A., All&eacute;e de la Recherche 60, B‑1070 Bruxelles, Belgium.</p><p>&nbsp;</p><p><strong>&nbsp;Batch releaser</strong></p><p>Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Germany .</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>UCB Pharma S.A., Chemin du Foriest, 1420 Braine L&rsquo;Alleud, Belgium</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in {06/2019 }.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>1.</strong><strong> </strong>&nbsp;<strong>ما هو دواء ڨيمبات؟ وفيم يُستخدم؟</strong></p><p dir="RTL"><strong>ما هو دواء ڨيمبات؟</strong></p><p dir="RTL">يحتوي دواء ڨيمبات على لاكوساميد.&nbsp; ينتمي هذا الدَّواء إلى مجموعة من الأدوية تسمى: &quot;مضادات الصرع&quot;. تستخدم هذه الأدوية في علاج الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لقد تم إعطاؤك هذا الدَّواء لخفض عدد التشنجات (النوبات التشنُّجية) التي تتعرَّض لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يُستخدم دواء ڨيمبات؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم دواء ڨيمبات في البالغين والمراهقين والأطفال من عمر 4 سنوات وأكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم لعلاج نوع معين من أنواع الصَّرع يتسم بحدوث نوبة تشنجية تظهر جزئيًّا مع تعميم ثانوي أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في هذا النوع من الصَّرَع، تُؤثر التشنجات أولًا على أحد جانبي المخ. مع ذلك، قد تنتشر بعد ذلك لتصيب مناطق أكبر على كلا جانبي المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن استخدام دواء ڤيمبات بمفرده أو مع مضادات الصَّرَع الأخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2.</strong><strong> </strong>&nbsp;<strong>ما الذي تحتاج إلى معرفته قبل استخدام دواء ڨيمبات؟</strong></p><p dir="RTL"><strong>&nbsp;</strong><strong>لا تستخدم دواء ڨيمبات</strong></p><ul><li dir="RTL">إذا كنت مصابًا بالحساسية تجاه مادة لاكوساميد أو أي من المكونات الأخرى لهذا الدواء &nbsp;)مدرجة في القسم السادس(. إذا كنت غير متأكد من أنك مُصاب بالحساسية، الرجاء مناقشة الأمر مع الطبيب.</li><li dir="RTL">إذا كان لديك نوع محدد من المشاكل المتعلقة بضربات القلب يُسمى الإحصار الأذيني البطيني من الدرجة الثانية أو الثالثة.</li></ul><p dir="RTL">لا تستخدم دواء ڨيمبات إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدَّث مع طبيبك أو الصيدلي الخاص بك قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL">تحدث إلى الطبيب قبل استخدام دواء ڨيمبات في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أفكار لإيذاء نفسك أو قتلها. قد عانى عدد قليل من الأشخاص الذين يتم علاجهم بالمنتجات الدَّوائية المضادة للصَّرع مثل: لاكوساميد من أفكار لإيذاء أو قتل أنفسهم. إذا كان لديك أيٌّ من هذه الأفكار في أي وقت، فأخبر طبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة بالقلب تُؤثر على ضربات القلب لديك وغالبًا ما تعاني من ضربات قلب بطيئة على وجه الخصوص أو سريعة أو غير منتظمة (مثل: الإحصار الأذيني البطيني، الرجفان الأذيني والرفرفة الأذينية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض قلبي شديد مثل: هبوط (فشل) القلب أو كنت قد أُصبت بنوبة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في كثير من الأحيان تشعر بالدوخة أو تتعرَّض للسقوط. قد يجعلك دواء ڨيمبات تشعر بدوخة- وهذا قد يرفع خطر حدوث إصابة عرضية أو سقوط. هذا يعني أنه عليك توخي الحذر حتى تعتاد على تأثيرات هذا الدَّواء.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام دواء ڨيمبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول دواء ڤيمبات وتعاني من أعراض دقات قلب غير طبيعية (مثل ضربات قلب بطيئة أو سريعة أو غير منتظمة، خفقان، ضيق النفس، الشعور بالدوار، الإغماء)، فاطلب المشورة الطبية فورًا (انظر القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong> <strong>الأقل من 4 سنوات</strong></p><p dir="RTL">لا يوصى باستعمال ڨيمبات للأطفال والمراهقين الذين تقل أعمارهم عن 4 سنوات. هذا لأننا لم نعلم بعد ما إذا كان سيعمل أم لا، وما إذا كان آمنًا على الأطفال في هذه الفئة العُمْرية أم لا.</p><p dir="RTL"><strong>تناول </strong><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.&nbsp;</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية التي تؤثر على القلب لديك -هذا لأنَّ دواء ڨيمبات قد يُؤثر أيضًا على القلب لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج مشاكل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تُزيد &quot;فاصل PR&quot; على فحص القلب (مُخَطط كهربية القلب) مثل:&nbsp; أدوية علاج الصَّرَع أو الألم التي تُسمى كاربامازيبين أو لاموترجين أو بريجابالين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج أنواع معينة من عدم انتظام ضربات القلب أو فشل القلب.</p><p dir="RTL">إذا &nbsp;كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام دواء ڨيمبات.</p><p dir="RTL">أيضًا، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية. وذلك بسبب أنها قد تزيد أو تخفض من تأثير دواء ڨيمبات في جسمك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج العدوى الفطرية التي تُسمى فلوكونازول أو إتراكونازول أو كيتوكونازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أدوية علاج فيروس نقص المناعة البشرية الذي يُسمى ريتونافير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج العدوى البكتيرية التي تُسمى كلاريثروميسين أو ريفامبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء عشبي يُستَخدَم لعلاج الحالات الطفيفة من القلق والاكتئاب يُسمى نبتة سانت جونز.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام دواء ڨيمبات.</p><p dir="RTL"><strong>تناول دواء</strong><strong> </strong><strong>ڨيمبات</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الكحول</strong></p><p dir="RTL">كأحد احتياطات الأمان لا تستخدم ڨيمبات مع الكحول.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة أو تظنين أنكِ حامل أو تخططين لإنجاب طفل، فاستشيرى طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;يُوصى بعدم استخدام دواء ڨيمبات إذا كنتِ حاملًا أو مرضعًا؛ إذ إن تأثيرات دواء ڨيمبات على الحمل وعلى الجنين وعلى الطفل حديث الولادة غير معروفة. أيضًا، من غير المعروف ما إذا كان يمر دواء ڨيمبات إلى لبن الأم أم لا. اطلبي المشورة فورًا من طبيبكِ إذا أصبحتِ حاملًا أو كنت تخططين للحَمْل. سيُساعِدونك على اتخاذ قرار بشأن ما إذا كان عليكِ استخدام دواء ڨيمبات أم لا.</p><p dir="RTL">&nbsp;يجب أَلَّا تتوقف عن العلاج دون التَّحدث إلى طبيبك أولًا؛ لأنَّ ذلك قد يزيد من حدوث التشنجات التي تعاني منها (النوبات التشنجية). قد يُؤدي تفاقم المرض لديكِ أيضًا إلى إلحاق الضَّرر بطفلك.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الماكينات</strong></p><p dir="RTL">لا تمارس قيادة المركبات أو ركوب الدراجات أو تستخدم أي أدوات أو آلات حتى تعرف كيفية تأثير هذا الدَّواء عليك. هذا لأنَّ دواء ڨيمبات قد يجعلك تشعر بالدوخة أو يُسبب لك عدم وضوح بالرؤية.</p><p dir="RTL"><strong>ڨيمبات يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدَّواء على 2,6 مللي مول &nbsp;)أو 59,8 ملغ ( من الصوديوم في كل زجاجة. إذا كنت تتبع نظامًا غذائيًّا منخفض الصوديوم، فأنت بحاجة إلى معرفة ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3.</strong><strong> </strong><strong>كيفية</strong><strong> </strong><strong>استخدام </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">استخدم هذا الدَّواء دائمًا بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. يُرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا تمامًا.</p><p dir="RTL"><strong>استخدام دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن بدء العلاج بدواء ڨيمبات عن طريق:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الدَّواء عن طريق الفم أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; عن طريق تلقي التَّسريب الوريدي والذي يعطيك فيه الطبيب أو الممرض(ة) الدَّواء في الوريد. يُعطى التَّسريب الوريدي على مدار 15 إلى 60 دقيقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستَخدَم التَّسريب الوريدي عادةً لفترة قصيرة عندما لا تتمكن من تناوُل الدَّواء عن طريق الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيقرر طبيبك كم عدد الأيام التي ستتلقى فيها التَّسريبات. هناك خبرة بشأن تلقي تَسريبات دواء ڨيمبات مرتين يوميًّا لمدة تصل إلى 5 أيام. يتوفر دواء ڨيمبات على هيئة أقراص وشراب للعلاج لفترة أطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما تغير العلاج من تلقي التَّسريب إلى العلاج بتناول الدَّواء عن طريق الفم (أو العكس) تظل الكمية الإجمالية التي تتناولها كل يوم هي نفسها وكذلك عدد مرَّات التَّناوُل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم دواء ڨيمبات مرَّتين كل يوم - مرّة في الصباح وأخرى في المساء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاول استخدامه في الوقت نفسه تقريبًا من كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما الكمية التي يجب أن تستخدمها؟</strong></p><p dir="RTL">مدرج أدناه الجرعات المعتادة الموصى بها لدواء ڨيمبات للفئات العمرية والأوزان المختلفة. قد يصف لك طبيبك جرعة مختلفة إذا كنت تعاني من مشاكل بالكلى أو الكبد.</p><p dir="RTL"><strong>المراهقون والأطفال الذين يزنون 50</strong>&nbsp;<strong> كجم أو أكثر</strong><strong> </strong><strong>والبالغون</strong></p><p dir="RTL"><u>عند استخدامك لدواء ڨيمبات بمفرده</u></p><p dir="RTL">جرعة البدء المعتادة من دواء ڨيمبات هي 50 ملغ مرتين في اليوم.</p><p dir="RTL">قد يبدأ أيضًا العلاج بدواء ڨيمبات بجرعة قدرها 100 ملغ من دواء ڨيمبات مرّتين في اليوم.</p><p dir="RTL">قد يرفع طبيبك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 50 ملغ. سيتم ذلك حتى تصل إلى جرعة مداومة تتراوح بين 100 ملغ و300 ملغ مرَّتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عند استخدام دواء ڨيمبات مع مضادات الصَّرَع الأخرى</u></p><p dir="RTL">جرعة البدء المعتادة من دواء ڨيمبات هي 50 ملغ مرّتين في اليوم.</p><p dir="RTL">قد يرفع طبيبك جرعتك التي تتلقاها مرَّتين يوميًّا كل أسبوع بمقدار 50 ملغ. سيتم ذلك حتى تصل إلى جرعة مداومة تتراوح بين 100 ملغ و200 ملغ مرَّتين في اليوم.</p><p dir="RTL">قد يقرر طبيبك بدء العلاج بدواء ڨيمبات بجرعة &quot;تحميل&quot; مفردة قدرها 200 ملغ، إذا كنت تزن 50 كجم أو أكثر. سوف تبدأ بعد ذلك في تناول جرعة المداومة المستمرة الخاصَّة بك بعد 12 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون الذين تقل أوزانهم عن 50</strong>&nbsp;<strong> كجم</strong></p><p dir="RTL"><u>عند استخدامك لدواء ڨيمبات بمفرده</u></p><p dir="RTL">سوف يقرر طبيبك جرعة دواء ڨيمبات وفقًا لوزن جسمك.</p><p dir="RTL">جرعة البدء المعتادة هي 1 ملغ (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتلقاها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغ (0.1 ملل) لكل كجم من وزن جسمك. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القُصوى المُوصى بها هي 6&nbsp; ملغ (0.6 ملل) لكل كجم من وزن الجسم، مرّتين في اليوم، بالنسبة إلى الأطفال الذين تقل أوزانهم عن 40 كجم. جرعة المُداومة القُصوى هي 5 ملغ (0.5 ملل) لكل كجم من وزن الجسم، مرّتين في اليوم، بالنسبة إلى الأطفال الذين تتراوح أوزانهم بين 40 كجم وأقل من 50 كجم. وارد أدناه مُخَططات الجرعات:</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدام دواء ڨيمبات يكون بمفرده - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم استخدامه مرتين يوميًّا</strong> بالنسبة للأطفال من عمر 4 سنوات<strong> الذين تقل أوزانهم عن 40 كجم</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.6 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">10 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1 ملل</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">15 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">20 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">25 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">15 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">30 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td><td style="vertical-align:top"><p dir="RTL">15 ملل</p></td><td style="vertical-align:top"><p dir="RTL">18 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">35 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">14 ملل</p></td><td style="vertical-align:top"><p dir="RTL">17.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">21 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم استخدامه مرّتين يوميًّا </strong>بالنسبة للأطفال والمراهقين من عمر 4 سنوات <strong>الذين</strong> <strong>تتراوح أوزانهم بين 40 كجم وأقل من 50 كجم:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">40 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td><td style="vertical-align:top"><p dir="RTL">16 ملل</p></td><td style="vertical-align:top"><p dir="RTL">20 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">45 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">13.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">18 ملل</p></td><td style="vertical-align:top"><p dir="RTL">22.5 ملل</p></td></tr></tbody></table><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>عند استخدام دواء ڨيمبات مع مضادات الصَّرَع الأخرى</u></p><p dir="RTL">سوف يقرر طبيبك جرعة دواء ڨيمبات وفقًا لوزن جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال من عمر 4 سنوات الذين تقل أوزانهم عن 20 كجم:</p><ul><li dir="RTL">جرعة البدء المعتادة هي 1 ملغ (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغ (0.1 ملل) لكل كجم من وزن الجسم. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القصوى الموصى بها هي 6 ملغ (0.6 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم. وارد أدناه مخطط الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدام دواء ڨيمبات مع الأدوية الأخرى المضادة للصَّرَع - <strong>الأطفال الذين تزيد أعمارهم عن 4 سنوات وتقل أوزانهم عن 20</strong>&nbsp;<strong> كجم</strong> - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم استخدامه مرتين يوميًّا </strong>بالنسبة للأطفال من عمر 4 سنوات<strong> الذين تقل أوزانهم عن 20 كجم</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.6 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">10 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1 ملل</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">15 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال من عمر 4 سنوات الذين تتراوح أوزانهم بين 20 كجم وأقل من 30 كجم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المُعتادة هي 1 ملغ (0.1 ملل) لكل كيلو جرام من وزن الجسم، مرّتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك جرعتك التي تتلقاها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغ (0.1 ملل) لكل كجم من وزن الجسم. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القصوى الموصى بها هي 5 ملغ (0.5 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم. وارد أدناه مخطط الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدام دواء ڨيمبات مع الأدوية الأخرى المضادة للصَّرَع - <strong>الأطفال والمراهقون ممن تتراوح أوزانهم بين 20 كجم وأقل من 30 كجم</strong> - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم استخدامه مرّتين يوميًّا </strong>بالنسبة للأطفال والمراهقين من عمر 4 سنوات <strong>الذين</strong> <strong>تتراوح أوزانهم بين 20 كجم وأقل من 30 كجم:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">20 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">25 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12.5 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال من عمر 4 سنوات الذين تتراوح أوزانهم بين 30 وأقل من 50 كجم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المعتادة هي 1 ملغ (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغ (0.1 ملل) لكل كجم من وزن الجسم. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القصوى الموصى بها هي 4 ملغ (0.4 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم. وارد أدناه مخطط الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدام دواء ڨيمبات مع الأدوية الأخرى المضادة للصَّرَع - <strong>الأطفال والمراهقون ممن تتراوح أوزانهم بين 30 كجم وأقل من 50 كجم</strong> - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم استخدامه مرّتين يوميًّا </strong>بالنسبة للأطفال والمراهقين من عمر 4 سنوات <strong>الذين</strong> <strong>تتراوح أوزانهم بين 30 كجم وأقل من&nbsp; 50 كجم:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">30 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">35 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">14 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">40 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td><td style="vertical-align:top"><p dir="RTL">16 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">45 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">13.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">18 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام دواء ڨيمبات</strong></p><p dir="RTL">في حالة قرر الطبيب إيقاف معالجتك باستخدام ڨيمبات، فسيقوم بخفض الجرعة خطوة بخطوة. هذا للوقاية من عودة الصَّرَع لديك مرة أخرى أو تفاقمه.</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى عن استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>.</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية على الرغم من عدم حدوث تلك الآثار الجانبية لكل من يتناوله.</p><p dir="RTL">قد تزيد الآثار الجانبية المتعلقة بالجهاز العصبي مثل الدوخة بعد تلقي جرعة &quot;التحميل&quot; المفردة.</p><p dir="RTL"><strong>تحدَّث إلى طبيبك أو الصيدلي الخاص بك إذا تعرضت لأي مما يلي:</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جدًا</strong>: قد تؤثر &nbsp;في أكثر من 1 من كل 10&nbsp;أشخاص</p><ul><li dir="RTL">الصداع.</li><li dir="RTL">شعور بدوخة أو إعياء (غثيان).</li><li dir="RTL">ازدواج الرؤية (شفع).</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر &nbsp;في ما يصل إلى 1 من كل 10&nbsp;أشخاص</p><ul><li dir="RTL">مشكلات في حفظ التوازن وارتجاف (رعاش)، &nbsp;و نخز (شعور غير عادى بالتنميل أو الحكة) أو تقلصات عضلية، السقوط بسهولة والإصابة بكدمات.</li><li dir="RTL">مشاكل بالذاكرة، التفكير أو إيجاد الكلمات وارتباك.</li><li dir="RTL">حركة العينين السريعة والتي لا يمكن السيطرة عليها (رَأْرَأَة)، عدم وضوح الرؤية.</li><li dir="RTL">شعور بالدوران (دوار)، شعور بالثمالة.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء (قيء) ، وجفافُ الفَم، وإمساك ، وعسر الهضم، &nbsp;وفرط الغازات في المعدة أو الأمعاء، وإسهال.</p><ul><li dir="RTL">ضعف الشعور أو الإحساس، صعوبة في نطق الكلمات، اضطراب في الانتباه.</li><li dir="RTL">ضجيج في الأذن مثل: الطنين، أو الرنين، أو الصفير.</li><li dir="RTL">هياج، صعوبات النوم، اكتئاب.</li><li dir="RTL">نعاس، تعب أو ضعف (وهن).</li><li dir="RTL">حكة، طفح جلدي.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر &nbsp;في ما يصل إلى 1 من كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء معدل ضربات القلب، خَفَقان، عدم انتظام النبض أو غير ذلك من التغيرات في النشاط الكهربي للقلب (اضطراب بالتَّوصيل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور مبالغ فيه بالصحة والعافية، رؤية و/ أو سماع أشياء غير موجودة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية لتناول الدواء، شرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُظهِر اختبارات الدَّم اضطرابات في وظائف الكبد، الإصابات الكبدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار لإيذاء نفسك أو قتلها أو محاولة الانتحار. أخبر طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالغضب أو الهياج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفكير بشكل غير طبيعي أو فقدان الاتصال مع الواقع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية حاد يُسبب تورمًا في الوجه أو الحلق أو اليد أو القدم أو الكاحلين أو أسفل الساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في تناسق حركاتك أو المشي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>معروفة</strong>: لا يمكن تقدير معدل التكرار من البيانات المُتاحة</p><ul><li dir="RTL">ضربات قلب سريعة غير طبيعية (اضْطِّراب النَّظْمِ التَّسَرُّعِيّ البطيني).</li><li dir="RTL">التهاب الحَلْق، ارتفاع درجة الحرارة والإصابة بالعدوى بصورة أكثر من المُعتاد. قد تظهر اختبارات الدَّم انخفاضًا حادًا في فئة معينة من خلايا الدم البيضاء (ندرة خلايا المحببات).</li><li dir="RTL">رد فعل جلدي حاد والذي قد يتضمن ارتفاع درجة الحرارة وأعراضًا أخرى مشابهة لأعراض الإنفلونزا ، طفح جلدى على الوجه، طفح جلدى منتشر ، تورُّم الغدد (تضخم العقد الليمفاوية). &nbsp;قد تُظهِر اختبارات الدَّم ارتفاع مستويات إنزيمات الكبد ، و أحد أنواع خلايا الدم البيضاء (كثرة خلايا اليُوزينِيَّات).</li><li dir="RTL">طفح منتشر مقرونًا ببثرات وتقشير الجلد، وخاصة حول الفم والأنف والعين والأعضاء التناسلية (متلازمة ستيفن جونسون)، وشكل أكثر حدة من الطفح يتسبب في تقشير الجلد في ما يزيد عن 30% من سطح الجسم (انحلال البشرة السام).</li><li dir="RTL">تشنجات.</li></ul><p dir="RTL"><strong>الآثار الجانبية الإضافية عند إعطاء الدواء في هيئة تسريب وريدي</strong></p><p dir="RTL">&nbsp;قد تكون هناك آثار جانبية موضعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر &nbsp;في ما يصل إلى 1 من كل 10&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو شعور غير مريح أو تهيُّج في موضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر &nbsp;في ما يصل إلى 1 من كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار بموضع الحقن.</p><p dir="RTL"><strong>الآثار الجانبية الإضافية في الأطفال </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة: </strong>قد تُؤثر في ما يصل إلى 1 من كل 10&nbsp;أطفال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف (التهاب البلعوم الأنفي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق (التهاب البلعوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الطعام بشكل أقل من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong>: قد تُؤثر في ما يصل إلى 1 من كل 100&nbsp;طفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالنُّعاس أو النَّقص في الطاقة(خمول).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong>: لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في السلوك، عدم التَّصرف على طبيعتهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي من الآثار الجانبية، فيُرجى إبلاغ الطبيب أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>.</strong><strong> </strong><strong>كيفية</strong><strong> </strong><strong>تخزين</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">يحفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على علبة الكرتون والزجاجة بعد الصيغة المختصرة EXP، يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر الموضح.</p><p dir="RTL">يحفظ في درجة حرارة &nbsp;لا تزيد عن &nbsp;30 درجة مئوية.</p><p dir="RTL">يجب استخدام كل زجاجة من محلول ڨيمبات المستخدم للتسريب مرة واحدة فقط (للاستخدام مرة واحدة). وينبغي التخلص من أي محلول لم يتم استخدامه.</p><p dir="RTL">يجب فقط استخدام المحاليل الصافية تمامًا والخالية من أية جزيئات أو تغير اللون.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تُستخدم. إذ تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>ما الذي يحتوي عليه ڨيمبات؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المادة الفعالة هي لاكوساميد.</p><p dir="RTL">يحتوي كل &nbsp;1 ملل من دواء ڨيمبات محلول للتَّسريب &nbsp;على 10 ملغ لاكوساميد.</p><p dir="RTL">تحتوي الزجاجة الواحدة سعة 20 ملل من دواء ڨيمبات محلول للتَّسريب بما يُعادِل 200 &nbsp;ملغ لاكوساميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كلوريد الصوديوم، حمض الهيدروكلوريك، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما شكل دواء ڨيمبات؟ وما محتويات العبوة؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ڨيمبات 10 ملغ/ملل محلول للتسريب هو محلول صاف عديم اللون.</p><p dir="RTL">يتوفر محلول التسريب ڨيمبات على شكل عبوات بها زجاجة واحدة سعة 20 ملل أو 5 زجاجات سعة 20 ملل. كل زجاجة تحتوي على 20 ملل.</p><p dir="RTL">قد لا تتوافر جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التفويض</strong><strong> </strong><strong>بالتسويق</strong><strong> </strong><strong>وجهة</strong><strong> </strong><strong>التصنيع</strong></p><p dir="RTL"><strong>مالك</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التفويض</strong><strong> </strong><strong>بالتسويق</strong></p><p dir="RTL">UCB Pharma S.A.,</p><p dir="RTL">All&eacute;e de la Recherche 60,</p><p dir="RTL">B‑1070 Bruxelles, Belgium.</p><p dir="RTL"><strong>Batch released by:</strong></p><p dir="RTL">Aesica Pharmaceuticals GmbH,</p><p dir="RTL">Alfred-Nobel Strasse 10, D-40789 Monheim Am Rhein, Germany.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة</strong><strong> </strong><strong>التصنيع</strong><strong>:</strong></p><p dir="RTL">UCB Pharma S.A.,</p><p dir="RTL">Chemin du Foriest, 1420 Braine L&rsquo;Alleud, Belgium.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة تمت في {2017/09}06/2019}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1.	NAME OF THE MEDICINAL PRODUCT

Vimpat 10 mg/ml solution for infusion


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.	QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of solution for infusion contains 10 mg lacosamide.
Each vial of 20 ml solution for infusion contains 200 mg lacosamide.

Excipients with known effect:
Each ml of solution for infusion contains 2.99 mg sodium. 

For the full list of excipients, see section 6.1


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3.	PHARMACEUTICAL FORM

Solution for infusion.
Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p><u>&nbsp;</u></p><p>Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4&nbsp;years of age with epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of administration</strong></p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Lacosamide therapy can be initiated with either oral or intravenous administration. Solution for infusion is an alternative for patients when oral administration is temporarily not feasible. The overall duration of treatment with intravenous lacosamide is at the physician&rsquo;s discretion; there is experience from clinical trials with twice daily infusions of lacosamide for up to 5&nbsp;days in adjunctive therapy. Conversion to or from oral and intravenous administration can be done directly without titration. The total daily dose and twice daily administration should be maintained. Monitor closely patients with known cardiac conduction problems, on concomitant medications that prolong PR interval, or with severe cardiac disease (e.g. myocardial ischemia, heart failure) when lacosamide dose is higher than 400&nbsp;mg/day (see Method of administration below and section 4.4).</p><p>Lacosamide must be taken twice a day (usually once in the morning and once in the evening).</p><p>&nbsp;</p><p><em><u>Adolescents and children </u></em><em><u>weighing 50&nbsp;kg or more, and adults</u></em></p><p>&nbsp;</p><p>The following table summarises the recommended posology for adolescents and children weighing 50&nbsp;kg or more, and for adults. More details are provided in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Monotherapy</p></td><td style="vertical-align:top"><p>Adjunctive therapy</p></td></tr><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>100&nbsp;mg/day or 200&nbsp;mg/day</p></td><td style="vertical-align:top"><p>100&nbsp;mg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p><p>(if applicable)</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>50&nbsp;mg twice a day (100&nbsp;mg/day) at weekly intervals</p></td><td style="vertical-align:top"><p>50&nbsp;mg twice a day (100&nbsp;mg/day) at weekly intervals</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose</p></td><td style="vertical-align:top"><p>up to 600&nbsp;mg/day</p></td><td style="vertical-align:top"><p>up to 400&nbsp;mg/day</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Monotherapy </em></p><p>The recommended starting dose is 50&nbsp;mg twice a day which should be increased to an initial therapeutic dose of 100&nbsp;mg twice a day after one week.</p><p>Lacosamide can also be initiated at the dose of 100&nbsp;mg twice a day based on the physician&#39;s assessment of required seizure reduction versus potential side effects.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50&nbsp;mg twice a day (100&nbsp;mg/day), up to a maximum recommended daily dose of 300&nbsp;mg twice a day (600&nbsp;mg/day).</p><p>In patients having reached a dose greater than 400&nbsp;mg/day and who need an additional antiepileptic medicinal product, the posology that is recommended for adjunctive therapy below should be followed.</p><p>&nbsp;</p><p><em>Adjunctive therapy </em></p><p>The recommended starting dose is 50&nbsp;mg twice a day which should be increased to an initial therapeutic dose of 100&nbsp;mg twice a day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50&nbsp;mg twice a day (100&nbsp;mg/day), up to a maximum recommended daily dose of 400&nbsp;mg (200&nbsp;mg twice a day).</p><p><u>&nbsp;</u></p><p><em>Initiation of lacosamide treatment with a loading dose </em></p><p>Lacosamide treatment may also be initiated with a single loading dose of 200&nbsp;mg, followed approximately 12&nbsp;hours later by a 100&nbsp;mg twice a day (200&nbsp;mg/day) maintenance dose regimen. Subsequent dose adjustments should be performed according to individual response and tolerability as described above. A loading dose may be initiated in patients in situations when the physician determines that rapid attainment of lacosamide steady state plasma concentration and therapeutic effect is warranted. It should be administered under medical supervision with consideration of the potential for increased incidence of serious cardiac arrhythmia and central nervous system adverse reactions (see section 4.8). Administration of a loading dose has not been studied in acute conditions such as status epilepticus.</p><p><em>&nbsp;</em></p><p><em>Discontinuation</em></p><p>In accordance with current clinical practice, if lacosamide has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200&nbsp;mg/week).</p><p>In patients who develop serious cardiac arrhythmia, clinical benefit/risk assessment should be performed and if needed lacosamide should be discontinued.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly (over 65 years of age)</em></p><p>No dose reduction is necessary in elderly patients. Age associated decreased renal clearance with an increase in AUC levels<strong> </strong>should be considered in elderly patients (see following paragraph &lsquo;renal impairment&rsquo; and section 5.2). There is limited clinical data in the elderly patients with epilepsy, particularly at doses greater than 400&nbsp;mg/day (see sections 4.4, 4.8, and 5.1).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in mildly and moderately renally impaired adult and paediatric patients (CL<sub>CR</sub> &gt;&nbsp;30&nbsp;ml/min). In paediatric patients weighing 50&nbsp;kg or more and in adult patients with mild or moderate renal impairment a loading dose of 200&nbsp;mg may be considered, but further dose titration (&gt;&nbsp;200&nbsp;mg daily) should be performed with caution. In paediatric patients weighing 50&nbsp;kg or more and in adult patients with severe renal impairment (CL<sub>CR</sub> &le;&nbsp;30&nbsp;ml/min) or with end-stage renal disease, a maximum dose of 250&nbsp;mg/day is recommended and the dose titration should be performed with caution. If a loading dose is indicated, an initial dose of 100&nbsp;mg followed by a 50&nbsp;mg twice daily regimen for the first week should be used. In paediatric patients weighing less than 50&nbsp;kg with severe renal impairment (CL<sub>CR</sub> &le;&nbsp;30&nbsp;ml/min) and in those with end-stage renal disease, a reduction of 25&nbsp;% of the maximum dose is recommended. For all patients requiring haemodialysis a supplement of up to 50&nbsp;% of the divided daily dose directly after the end of haemodialysis is recommended. Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity).</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>A maximum dose of 300&nbsp;mg/day is recommended for paediatric patients weighing 50&nbsp;kg or more and for adult patients with mild to moderate hepatic impairment.</p><p>The dose titration in these patients should be performed with caution considering co-existing renal impairment. In adolescents and adults weighing 50&nbsp;kg or more, a loading dose of 200&nbsp;mg may be considered, but further dose titration (&gt;&nbsp;200&nbsp;mg daily) should be performed with caution. Based on data in adults, in paediatric patients weighing less than 50&nbsp;kg with mild to moderate hepatic impairment a reduction of 25% of the maximum dose should be applied. The pharmacokinetics of lacosamide has not been evaluated in severely hepatic impaired patients (see section 5.2). Lacosamide should be administered to adult and paediatric patients with severe hepatic impairment only when the expected therapeutic benefits are anticipated to outweigh the possible risks. The dose may need to be adjusted while carefully observing disease activity and potential side effects in the patient.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><em>&nbsp;</em></p><p>The physician should prescribe the most appropriate formulation and strength according to weight and dose.</p><p>&nbsp;</p><p><em><u>Adolescents and children weighing 50&nbsp;kg or more </u></em></p><p>Dosage in adolescents and children weighing 50&nbsp;kg or more is the same as in adults (see above).</p><p>&nbsp;</p><p><em><u>C</u></em><em><u>hildren (from 4&nbsp;years of age) and adolescents weighing less than 50&nbsp;kg</u></em></p><p><em>&nbsp;</em></p><p><em>Monotherapy </em></p><p>The recommended starting dose is 2&nbsp;mg/kg/day which should be increased to an initial therapeutic dose of 4&nbsp;mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2&nbsp;mg/kg/day every week. The dose should be gradually increased until the optimum response is obtained. In children weighing less than 40&nbsp;kg, a maximum dose of up to 12&nbsp;mg/kg/day is recommended. In children weighing from 40 to under 50&nbsp;kg, a maximum dose of 10&nbsp;mg/kg/day is recommended.</p><p>&nbsp;</p><p>The following table below summarises the recommended posology in monotherapy for children and adolescents weighing less than 50&nbsp;kg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day every week</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 12&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;40&nbsp;kg to &lt;&nbsp;50&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 10&nbsp;mg/kg/day</p></td></tr></tbody></table><p>&nbsp;</p><p>The tables below provide examples of volumes of solution for infusion per administration depending on prescribed dose and body weight. The precise volume of solution for infusion is to be calculated according to the exact body weight of the child.</p><p>&nbsp;</p><p>Monotherapy doses <strong>to be taken twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 40&nbsp;kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p></td><td style="vertical-align:top"><p>0.6 ml/kg</p><p>(6 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p><p>(10 mg)</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p><p>(15 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4.5 ml</p><p>(45 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>8 ml</p><p>(80 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td><td style="vertical-align:top"><p>12 ml</p><p>(120 mg)</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p><p>(25 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td><td style="vertical-align:top"><p>12.5 ml</p><p>(125 mg)</p></td><td style="vertical-align:top"><p>15 ml</p><p>(150 mg)</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td><td style="vertical-align:top"><p>12 ml</p><p>(120 mg)</p></td><td style="vertical-align:top"><p>15 ml</p><p>(150 mg)</p></td><td style="vertical-align:top"><p>18 ml</p><p>(180 mg)</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml</p><p>(35 mg)</p></td><td style="vertical-align:top"><p>7 ml</p><p>(70 mg)</p></td><td style="vertical-align:top"><p>10.5 ml</p><p>(105 mg)</p></td><td style="vertical-align:top"><p>14 ml</p><p>(140 mg)</p></td><td style="vertical-align:top"><p>17.5 ml</p><p>(175 mg)</p></td><td style="vertical-align:top"><p>21 ml</p><p>(210 mg)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>(1) </sup>Children and adolescents less than 50&nbsp;kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup. Vimpat 10&nbsp;mg/ml solution for infusion is an alternative for patients when oral administration is temporarily not feasible.</p></td></tr></tbody></table><p>&nbsp;</p><p>Monotherapy doses <strong>to be taken twice daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 40&nbsp;kg to under 50&nbsp;kg</strong><sup>(1) (2)</sup>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>8 ml</p><p>(80 mg)</p></td><td style="vertical-align:top"><p>12 ml</p><p>(120 mg)</p></td><td style="vertical-align:top"><p>16 ml</p><p>(160 mg)</p></td><td style="vertical-align:top"><p>20 ml</p><p>(200 mg)</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml</p><p>(45 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td><td style="vertical-align:top"><p>13.5 ml</p><p>(135 mg)</p></td><td style="vertical-align:top"><p>18 ml</p><p>(180 mg)</p></td><td style="vertical-align:top"><p>22.5 ml</p><p>(225 mg)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>(1) </sup>Children and adolescents less than 50&nbsp;kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup. Vimpat 10&nbsp;mg/ml solution for infusion is an alternative for patients when oral administration is temporarily not feasible.</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>(2) </sup>Dosage in adolescents 50&nbsp;kg or more is the same as in adults.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Adjunctive therapy</em></p><p>The recommended starting dose is 2&nbsp;mg/kg/day which should be increased to an initial therapeutic dose of 4&nbsp;mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2&nbsp;mg/kg/day every week. The dose should be gradually adjusted until the optimum response is obtained. In children weighing less than 20&nbsp;kg, due to an increased clearance compared to adults, a maximum dose of up to 12&nbsp;mg/kg/day is recommended. In children weighing from 20 to under 30&nbsp;kg, a maximum dose of 10&nbsp;mg/kg/day is recommended and in children weighing from 30 to under 50&nbsp;kg a maximum dose of 8&nbsp;mg/kg/day is recommended, although in open-label studies (see sections 4.8 and 5.2), a dose up to 12&nbsp;mg/kg/day has been used by a small number of these children.</p><p>&nbsp;</p><p>The following table below summarises the recommended posology in adjunctive therapy for children and adolescents weighing less than 50&nbsp;kg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day every week</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &lt;&nbsp;20&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 12&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;20&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 10&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;30&nbsp;kg to &lt;&nbsp;50&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 8&nbsp;mg/kg/day</p></td></tr></tbody></table><p>&nbsp;</p><p>The tables below provide guidance on the volume of solution for infusion per administration depending on prescribed dose and body weight. The precise volume of solution for infusion is to be calculated according to the exact body weight of the child.</p><p>&nbsp;</p><p>Adjunctive therapy doses <strong>to be taken twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than</strong> <strong>20 kg</strong><sup>(1)</sup><strong>:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p></td><td style="vertical-align:top"><p>0.6 ml/kg</p><p>(6 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p><p>(10 mg)</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p><p>(15 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4.5 ml</p><p>(45 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>(1) </sup>Children and adolescents less than 50 kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup. Vimpat 10&nbsp;mg/ml solution for infusion is an alternative for patients when oral administration is temporarily not feasible.</p></td></tr></tbody></table><p>&nbsp;</p><p>Adjunctive therapy doses <strong>to be taken twice daily</strong> for children and adolescents from 4 years of age <strong>weighing 20</strong> <strong>kg to under 30 kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>8 ml</p><p>(80 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p><p>(25 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td><td style="vertical-align:top"><p>12.5 ml</p><p>(125 mg)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>(1) </sup>Children and adolescents less than 50 kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup. Vimpat 10&nbsp;mg/ml solution for infusion is an alternative for patients when oral administration is temporarily not feasible.</p></td></tr></tbody></table><p>&nbsp;</p><p>Adjunctive therapy doses <strong>to be taken twice daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 30</strong> <strong>kg to under 50 kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml (30 mg)</p></td><td style="vertical-align:top"><p>6 ml (60 mg)</p></td><td style="vertical-align:top"><p>9 ml (90 mg)</p></td><td style="vertical-align:top"><p>12 ml (120 mg)</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml (35 mg)</p></td><td style="vertical-align:top"><p>7 ml (70 mg)</p></td><td style="vertical-align:top"><p>10.5 ml (105 mg)</p></td><td style="vertical-align:top"><p>14 ml (140 mg)</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml (40 mg)</p></td><td style="vertical-align:top"><p>8 ml (80 mg)</p></td><td style="vertical-align:top"><p>12 ml (120 mg)</p></td><td style="vertical-align:top"><p>16 ml (160 mg)</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml (45 mg)</p></td><td style="vertical-align:top"><p>9 ml (90 mg)</p></td><td style="vertical-align:top"><p>13.5 ml (135 mg)</p></td><td style="vertical-align:top"><p>18 ml (180 mg)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>(1) </sup>Children and adolescents less than 50 kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup. Vimpat 10&nbsp;mg/ml solution for infusion is an alternative for patients when oral administration is temporarily not feasible.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Loading dose</em></p><p>Administration of a loading dose has not been studied in children. Use of a loading dose is not recommended in adolescents and children weighing less than 50&nbsp;kg.</p><p>&nbsp;</p><p><em><u>Children less than 4 years</u></em></p><p>The safety and efficacy of lacosamide in children aged below 4&nbsp;years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>The solution for infusion is infused over a period of 15 to 60&nbsp;minutes twice a day. An infusion duration of at least 30&nbsp;minutes for administration &gt;&nbsp;200&nbsp;mg per infusion (i.e. &gt;&nbsp;400&nbsp;mg/day) is preferred.</p><p>Vimpat solution for infusion can be administered intravenously without further dilution or can be diluted with sodium chloride 9&nbsp;mg/ml (0.9&nbsp;%) solution for injection, glucose 50&nbsp;mg/ml (5&nbsp;%) solution for injection or lactated Ringer&rsquo;s solution for injection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known second- or third-degree atrioventricular (AV) block. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p><u>&nbsp;</u></p><p><u>Suicidal ideation and behaviour</u></p><p>&nbsp;</p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic medicinal products in several indications. A meta-analysis of randomised placebo-controlled trials of antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for lacosamide.</p><p>Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge (see section 4.8).</p><p>&nbsp;</p><p><u>Cardiac rhythm and conduction</u></p><p>&nbsp;</p><p>Dose-related prolongations in PR interval with lacosamide have been observed in clinical studies. Lacosamide should be used with caution in patients with underlying proarrhythmic conditions such as patients with known cardiac conduction problems or severe cardiac disease (e.g. myocardial ischaemia/infarction, heart failure, structural heart disease or cardiac sodium channelopathies) or patients treated with medicinal products affecting cardiac conduction, including antiarrhythmics and sodium channel blocking antiepileptic medicinal products (see section 4.5), as well as in elderly patients.</p><p>In these patients it should be considered to perform an ECG before a lacosamide dose increase above 400&nbsp;mg/day and after lacosamide is titrated to steady-state.</p><p>&nbsp;</p><p>In the placebo-controlled trials of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however, both have been reported in open-label epilepsy trials and in post-marketing experience.</p><p>&nbsp;</p><p>In post-marketing experience, AV block (including second degree or higher AV block) has been reported. In patients with proarrhythmic conditions, ventricular tachyarrhythmia has been reported. In rare cases, these events have led to asystole, cardiac arrest and death in patients with underlying proarrhythmic conditions.</p><p>&nbsp;</p><p>Patients should be made aware of the symptoms of cardiac arrhythmia (e.g. slow, rapid or irregular pulse, palpitations, shortness of breath, feeling lightheaded, fainting). Patients should be counselled to seek immediate medical advice if these symptoms occur.</p><p>&nbsp;</p><p><u>Dizziness</u></p><p>&nbsp;</p><p>Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine (see section 4.8).</p><p>&nbsp;</p><p>This medicinal product contains 2.6&nbsp;mmol (or 59.8&nbsp;mg) sodium per vial. To be taken into consideration for patients on a controlled sodium diet.</p><p>&nbsp;</p><p><u>Potential for electro-clinical worsening in specific paediatric epilepsy syndromes</u></p><p>&nbsp;</p><p>The safety and efficacy of lacosamide in paediatric patients with epilepsy syndromes in which focal and generalised seizures may coexist have not been determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other medicinal products and other forms of interaction</strong></p><p><strong>&nbsp;</strong></p><p>Lacosamide should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (including sodium channel blocking antiepileptic medicinal products) and in patients treated with antiarrhythmics. However, subgroup analysis in clinical trials did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine.</p><p>&nbsp;</p><p><em><u>In vitro</u></em><u> data</u></p><p>&nbsp;</p><p>Data generally suggest that lacosamide has a low interaction potential. <em>In vitro</em> studies indicate that the enzymes CYP1A2, CYP2B6, and CYP2C9 are not induced and that CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP2E1 are not inhibited by lacosamide at plasma concentrations observed in clinical trials. An <em>in vitro</em> study indicated that lacosamide is not transported by P‑glycoprotein in the intestine. <em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite.</p><p><em>&nbsp;</em></p><p><em><u>In vivo</u></em><u> data</u></p><p>&nbsp;</p><p>Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent. Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given 200&nbsp;mg twice a day) but C<sub>max</sub> of midazolam was slightly increased (30&nbsp;%). Lacosamide did not affect the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given 300&nbsp;mg twice a day).</p><p>The CYP2C19 inhibitor omeprazole (40&nbsp;mg once daily) did not give rise to a clinically significant change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic lacosamide exposure to a clinically relevant extent.</p><p>Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g. fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead to increased systemic exposure of lacosamide. Such interactions have not been established <em>in vivo</em> but are possible based on <em>in vitro</em> data.</p><p>&nbsp;</p><p>Strong enzyme inducers such as rifampicin or St.&nbsp;John&rsquo;s wort (Hypericum perforatum) may moderately reduce the systemic exposure of lacosamide. Therefore, starting or ending treatment with these enzyme inducers should be done with caution.</p><p>&nbsp;</p><p><u>Antiepileptic medicinal products</u></p><p>&nbsp;</p><p>In interaction trials lacosamide did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid. Population pharmacokinetic analyses in different age groups estimated that concomitant treatment with other antiepileptic medicinal products known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25&nbsp;% in adults and 17&nbsp;% in paediatric patients.</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>In an interaction trial there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered.</p><p>&nbsp;</p><p><u>Others</u></p><p>&nbsp;</p><p>Interaction trials showed that lacosamide had no effect on the pharmacokinetics of digoxin. There was no clinically relevant interaction between lacosamide and metformin.</p><p>Co-administration of warfarin with lacosamide does not result in a clinically relevant change in the pharmacokinetics and pharmacodynamics of warfarin.</p><p>Although no pharmacokinetic data on the interaction of lacosamide with alcohol are available, a pharmacodynamic effect cannot be excluded.</p><p>Lacosamide has a low protein binding of less than 15&nbsp;%. Therefore, clinically relevant interactions with other medicinal products through competition for protein binding sites are considered unlikely.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</strong></p><p><em>&nbsp;</em></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p><em>Risk related to epilepsy and antiepileptic medicinal products in general </em></p><p>For all antiepileptic medicinal products, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3&nbsp;% in the general population. In the treated population, an increase in malformations has been noted with polytherapy, however, the extent to which the treatment and/or the illness is responsible has not been elucidated.</p><p>Moreover, effective antiepileptic therapy must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.</p><p>&nbsp;</p><p><em>Risk related to lacosamide</em></p><p>There are no adequate data from the use of lacosamide in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats and rabbits at maternal toxic doses (see section 5.3). The potential risk for humans is unknown.</p><p>Lacosamide should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>It is unknown whether lacosamide is excreted in human breast milk. A risk to the newborns/infants cannot be excluded. Animal studies have shown excretion of lacosamide in breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.</p><p><strong>&nbsp;</strong></p><p><u>Fertility</u></p><p>&nbsp;</p><p>No adverse reactions on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2 times the plasma AUC in humans at the maximum recommended human dose (MRHD).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use machines</strong></p><p>&nbsp;</p><p>Lacosamide has minor to moderate influence on the ability to drive and use machines. Lacosamide treatment has been associated with dizziness or blurred vision.</p><p>Accordingly, patients should be advised not to drive or to operate other potentially hazardous machinery until they are familiar with the effects of lacosamide on their ability to perform such activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</strong></p><p>&nbsp;</p><p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>Based on the analysis of pooled placebo-controlled clinical trials in adjunctive therapy in 1,308&nbsp;patients with partial-onset seizures, a total of 61.9&nbsp;% of patients randomised to lacosamide and 35.2&nbsp;% of patients randomised to placebo reported at least 1&nbsp;adverse reaction. The most frequently reported adverse reactions (&ge;&nbsp;10&nbsp;%) with lacosamide treatment were dizziness, headache, nausea and diplopia. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of central nervous system (CNS) and gastrointestinal (GI) adverse reactions usually decreased over time.</p><p>In all of these controlled studies, the discontinuation rate due to adverse reactions was 12.2&nbsp;% for patients randomised to lacosamide and 1.6&nbsp;% for patients randomised to placebo. The most common adverse reaction resulting in discontinuation of lacosamide therapy was dizziness.</p><p>Incidence of CNS adverse reactions such as dizziness may be higher after a loading dose.</p><p>&nbsp;</p><p>Based on the analysis of data from a non-inferiority monotherapy clinical trial comparing lacosamide to carbamazepine controlled release (CR), the most frequently reported adverse reactions (&ge;&nbsp;10&nbsp;%) for lacosamide were headache and dizziness. The discontinuation rate due to adverse reactions was 10.6&nbsp;% for patients treated with lacosamide and 15.6&nbsp;% for patients treated with carbamazepine CR.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The table below shows the frequencies of adverse reactions which have been reported in clinical trials and post-marketing experience. The frequencies are defined as follows: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100) and not known (frequency cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug hypersensitivity<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)<sup> (1,2)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p><p>Confusional state</p><p>Insomnia<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Aggression</p><p>Agitation<sup>(1)</sup></p><p>Euphoric mood<sup>(1)</sup></p><p>Psychotic disorder<sup>(1)</sup></p><p>Suicide attempt<sup> (1)</sup></p><p>Suicidal ideation</p><p>Hallucination<sup> (1)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Balance disorder</p><p>Memory impairment</p><p>Cognitive disorder</p><p>Somnolence</p><p>Tremor</p><p>Nystagmus</p><p>Hypoesthesia</p><p>Dysarthria</p><p>Disturbance in attention</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Syncope<sup>(2)</sup></p><p>Coordination abnormal</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion<sup>(3)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atrioventricular block<sup>(1,2)</sup></p><p>Bradycardia<sup>(1,2)</sup></p><p>Atrial Fibrillation <sup>(1,2)</sup></p><p>Atrial Flutter <sup>(1,2)</sup></p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmia <sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Constipation</p><p>Flatulence</p><p>Dyspepsia</p><p>Dry mouth</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function test abnormal<sup>(2)</sup></p><p>Hepatic enzyme increased (&gt;&nbsp;2x&nbsp;ULN)<sup> (1)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Angioedema<sup>(1)</sup></p><p>Urticaria<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>(1)</sup></p><p>Toxic epidermal necrolysis<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gait disturbance</p><p>Asthenia</p><p>Fatigue</p><p>Irritability</p><p>Feeling drunk</p><p>Injection site pain or discomfort <sup>(4)</sup></p><p>Irritation<sup>(4)</sup></p></td><td style="vertical-align:top"><p>Erythema<sup>(4)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p><p>Skin laceration</p><p>Contusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>(1) </sup>Adverse reactions reported in post marketing experience.</p><p><sup>(2) </sup>See Description of selected adverse reactions.</p><p><sup>(3)</sup> Reported in open-label studies.</p><p><sup>(4)</sup> Local adverse reactions associated with intravenous administration.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>The use of lacosamide is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur.</p><p>In adjunctive clinical trials in epilepsy patients the incidence rate of reported first-degree AV Block is uncommon, 0.7&nbsp;%, 0&nbsp;%, 0.5&nbsp;% and 0&nbsp;%<strong> </strong>for lacosamide 200&nbsp;mg, 400&nbsp;mg, 600&nbsp;mg or placebo, respectively. No second- or higher degree AV Block was seen in these studies. However, cases with second- and third-degree AV Block associated with lacosamide treatment have been reported in post-marketing experience. In the monotherapy clinical trial comparing lacosamide to carbamazepine CR the extent of increase in PR interval was comparable between lacosamide and carbamazepine.</p><p>The incidence rate for syncope reported in pooled adjunctive therapy clinical trials is uncommon and did not differ between lacosamide (n=944) treated epilepsy patients (0.1&nbsp;%) and placebo (n=364) treated epilepsy patients (0.3&nbsp;%). In the monotherapy clinical trial comparing lacosamide to carbamazepine CR, syncope was reported in 7/444 (1.6&nbsp;%) lacosamide patients and in 1/442 (0.2&nbsp;%) carbamazepine CR patients.</p><p>Atrial fibrillation or flutter were not reported in short term clinical trials; however, both have been reported in open-label epilepsy trials and in post-marketing experience.</p><p>&nbsp;</p><p><em>Laboratory abnormalities</em></p><p>Abnormalities in liver function tests have been observed in placebo-controlled trials with lacosamide in adult patients with partial-onset seizures who were taking 1 to 3 concomitant antiepileptic medicinal products. Elevations of ALT to &ge;&nbsp;3x&nbsp;ULN occurred in 0.7&nbsp;% (7/935) of Vimpat patients and 0&nbsp;% (0/356) of placebo patients.</p><p><u>&nbsp;</u></p><p><em>Multiorgan hypersensitivity reactions</em></p><p>Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) have been reported in patients treated with some antiepileptic medicinal products. These reactions are variable in expression but typically present with fever and rash and can be associated with involvement of different organ systems. If multiorgan hypersensitivity reaction is suspected, lacosamide should be discontinued.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety profile of lacosamide in placebo-controlled (see study details in section 5.1) and in open-label studies (n=408) in adjunctive therapy in children from 4&nbsp;years of age was consistent with the safety profile observed in adults although the frequency of some adverse reactions (somnolence, vomiting and convulsion) was increased and additional adverse reactions (nasopharyngitis, pyrexia, pharyngitis, decreased appetite, lethargy and abnormal behaviour) have been reported in paediatric patients: nasopharyngitis (15.7&nbsp;%), vomiting (14.7&nbsp;%), somnolence (14.0&nbsp;%), dizziness (13.5&nbsp;%), pyrexia (13.0&nbsp;%), convulsion (7.8&nbsp;%), decreased appetite (5.9&nbsp;%), pharyngitis (4.7 %), lethargy (2.7&nbsp;%) and abnormal behaviour (1.7&nbsp;%).</p><p>A total of 67.8 % of patients randomised to lacosamide and 58.1 % of patients randomised to placebo reported at least 1 adverse reaction.</p><p>Behavioural, cognition and emotional functioning were measured by the questionnaires Achenbach CBCL and BRIEF that were applied at baseline and throughout the studies and where mainly stable during the course of the trials.</p><p>&nbsp;</p><p><u>Elderly population </u></p><p>&nbsp;</p><p>In the monotherapy study comparing lacosamide to carbamazepine CR, the types of adverse reactions related to lacosamide in elderly patients (&ge;&nbsp;65&nbsp;years of age) appear to be similar to that observed in patients less than 65&nbsp;years of age. However, a higher incidence (&ge;&nbsp;5&nbsp;% difference) of fall, diarrhoea and tremor has been reported in elderly patients compared to younger adult patients. The most frequent cardiac-related adverse reaction reported in elderly compared to the younger adult population was first-degree AV block. This was reported with lacosamide in 4.8&nbsp;% (3/62) in elderly patients versus 1.6&nbsp;% (6/382) in younger adult patients. The discontinuation rate due to adverse events observed with lacosamide was 21.0&nbsp;% (13/62) in elderly patients versus 9.2&nbsp;% (35/382) in younger adult patients. These differences between elderly and younger adult patients were similar to those observed in the active comparator group.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</strong></p><p>&nbsp;</p><p><u>Symptoms</u></p><p><em>&nbsp;</em></p><p>Symptoms observed after an accidental or intentional overdose of lacosamide are primarily associated with CNS and gastrointestinal system.</p><ul><li>The types of adverse reactions experienced by patients exposed to doses above 400&nbsp;mg up to 800&nbsp;mg were not clinically different from those of patients administered recommended doses of lacosamide.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions reported after an intake of more than 800&nbsp;mg are dizziness, nausea, vomiting, seizures (generalised tonic-clonic seizures, status epilepticus). Cardiac conduction disorders, shock and coma have also been observed. Fatalities have been reported in patients following an intake of acute single overdose of several grams of lacosamide.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>There is no specific antidote for overdose with lacosamide. Treatment of lacosamide overdose should include general supportive measures and may include haemodialysis if necessary (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX18</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The active substance, lacosamide (R‑2‑acetamido‑N‑benzyl‑3‑methoxypropionamide) is a functionalised amino acid.</p><p>The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated. <em>In vitro</em> electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes.<s> </s></p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Lacosamide protected against seizures in a broad range of animal models of partial and primary generalised seizures and delayed kindling development.</p><p>In non-clinical experiments lacosamide in combination with levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, topiramate or gabapentin showed synergistic or additive anticonvulsant effects.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><u>Adult population</u></p><p><em>&nbsp;</em></p><p><em>Monotherapy</em></p><p>Efficacy of lacosamide as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine CR in 886 patients 16&nbsp;years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial-onset seizures with or without secondary generalisation. The patients were randomised to carbamazepine CR or lacosamide, provided as tablets, in a 1:1 ratio. The dose was based on dose-response and ranged from 400 to 1,200&nbsp;mg/day for carbamazepine CR and from 200 to 600&nbsp;mg/day for lacosamide. The duration of the treatment was up to 121&nbsp;weeks depending on the response.</p><p>The estimated 6-month seizure freedom rates were 89.8&nbsp;% for lacosamide-treated patients and 91.1&nbsp;% for carbamazepine CR treated patients using the Kaplan-Meier survival analysis method. The adjusted absolute difference between treatments was -1.3&nbsp;% (95&nbsp;% CI: -5.5, 2.8). The Kaplan-Meier estimates of 12-month seizure freedom rates were 77.8&nbsp;% for lacosamide-treated patients and 82.7&nbsp;% for carbamazepine CR treated patients.</p><p>The 6-month seizure freedom rates in elderly patients of 65 and above (62&nbsp;patients in lacosamide, 57&nbsp;patients in carbamazepine CR) were similar between both treatment groups. The rates were also similar to those observed in the overall population. In the elderly population, the maintenance lacosamide dose was 200&nbsp;mg/day in 55&nbsp;patients (88.7&nbsp;%), 400&nbsp;mg/day in 6&nbsp;patients (9.7&nbsp;%) and the dose was escalated to over 400&nbsp;mg/day in 1&nbsp;patient (1.6&nbsp;%).</p><p>&nbsp;</p><p><em>Conversion to monotherapy</em></p><p>The efficacy and safety of lacosamide in conversion to monotherapy has been assessed in a historical-controlled, multicentre, double-blind, randomised trial. In this study, 425&nbsp;patients aged 16 to 70&nbsp;years with uncontrolled partial-onset seizures taking stable doses of 1 or 2 marketed antiepileptic medicinal products were randomised to be converted to lacosamide monotherapy (either 400&nbsp;mg/day or 300&nbsp;mg/day in a 3:1 ratio). In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5&nbsp;% and 70.7&nbsp;% of patients respectively for 57-105&nbsp;days (median 71&nbsp;days), over the targeted observation period of 70&nbsp;days.</p><p>&nbsp;</p><p><strong><em>Adjunctive therapy</em></strong></p><p><strong>The efficacy of lacosamide as adjunctive therapy at recommended doses (200&nbsp;mg/day, 400&nbsp;mg/day) was established in 3 multicenter, randomised, placebo-controlled clinical trials with a 12‑week maintenance period. Lacosamide 600&nbsp;mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400&nbsp;mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse reactions. Thus, the 600&nbsp;mg/day dose is not recommended. The maximum recommended dose is 400&nbsp;mg/day. These trials, involving 1,308&nbsp;patients with a history of an average of 23&nbsp;years of partial-onset seizures, were designed to evaluate the efficacy and safety of lacosamide when administered concomitantly with 1‑3 </strong>antiepileptic medicinal products <strong>in patients with uncontrolled partial-onset seizures with or without secondary generalisation. </strong>Overall the proportion of subjects with a 50&nbsp;% reduction in seizure frequency was 23&nbsp;%, 34&nbsp;%, and 40&nbsp;% for placebo, lacosamide 200&nbsp;mg/day and lacosamide 400&nbsp;mg/day.</p><p>&nbsp;</p><p><strong>The pharmacokinetics and safety of a single loading dose of intravenous lacosamide were determined in a multicenter, open-label study designed to assess the safety and tolerability of rapid initiation of lacosamide using a single intravenous loading dose (including 200</strong>&nbsp;<strong>mg) followed by twice daily oral dosing (equivalent to the intravenous dose) as adjunctive therapy in adult subjects 16 to 60&nbsp;years of age with partial-onset seizures. </strong></p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Partial-onset seizures have a similar clinical expression in children from 4&nbsp;years of age and in adults. The efficacy of lacosamide in children aged 4&nbsp;years and older has been extrapolated from data of adolescents and adults with partial-onset seizures, for whom a similar response was expected provided the paediatric dose adaptations are established (see section 4.2) and safety has been demonstrated (see section 4.8).</p><p>The efficacy supported by the extrapolation principle stated above was confirmed by a double-blind, randomised, placebo-controlled study. The study consisted of an 8-week baseline period followed by a 6-week titration period. Eligible patients on a stable dose regimen of 1 to &le;&nbsp;3&nbsp;antiepileptic medicinal products, who still experienced at least 2&nbsp;partial onset seizures during the 4&nbsp;weeks prior to screening with seizure-free phase no longer than 21&nbsp;days in the 8-week period prior to entry into the baseline period, were randomised to receive either placebo (n=172) or lacosamide (n=171).</p><p>Dosing was initiated at a dose of 2&nbsp;mg/kg/day in subjects weighing less than 50&nbsp;kg or 100&nbsp;mg/day in subjects weighing 50&nbsp;kg or more in 2 divided doses. During the titration period, lacosamide doses were adjusted in 1or 2&nbsp;mg/kg/day increments in subjects weighing less than 50&nbsp;kg or 50 or 100&nbsp;mg/day in subjects weighing 50&nbsp;kg or more at weekly intervals to achieve the target maintenance period dose range.</p><p>Subjects must have achieved the minimum target dose for their body weight category for the final 3&nbsp;days of the titration period to be eligible for entry into the 10-week maintenance period. Subjects were to remain on stable lacosamide dose throughout the maintenance period or were withdrawn and entered in the blinded taper period.</p><p>Statistically significant (p=0.0003) and clinically relevant reduction in partial-onset seizure frequency per 28&nbsp;days from baseline to the maintenance period was observed between the lacosamide and the placebo group. The percent reduction over placebo based on analysis of covariance was 31.72&nbsp;% (95&nbsp;% CI: 16.342,44.277).</p><p>Overall, the proportion of subjects with at least a 50&nbsp;% reduction in partial-onset seizure frequency per 28&nbsp;days from baseline to the maintenance period was 52.9&nbsp;% in the lacosamide group compared with 33.3&nbsp;% in the placebo group.</p><p>The quality of life assessed by the Pediatric Quality of Life Inventory indicated that subjects in both lacosamide and placebo groups had a similar and stable health-related quality of life during the entire treatment period.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p>&nbsp;</p><p><u>Absorption </u></p><p>&nbsp;</p><p>After intravenous administration, C<sub>max</sub> is reached at the end of infusion. The plasma concentration increases proportionally with dose after oral (100‑800&nbsp;mg) and intravenous (50‑300&nbsp;mg) administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution is approximately 0.6&nbsp;L/kg. Lacosamide is less than 15&nbsp;% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>95&nbsp;% of the dose is excreted in the urine as lacosamide and metabolites. The metabolism of lacosamide has not been completely characterised.</p><p>The major compounds excreted in urine are unchanged lacosamide (approximately 40&nbsp;% of the dose) and its O‑desmethyl metabolite less than 30&nbsp;%.</p><p>A polar fraction proposed to be serine derivatives accounted for approximately 20&nbsp;% in urine, but was detected only in small amounts (0‑2&nbsp;%) in human plasma of some subjects. Small amounts (0.5‑2&nbsp;%) of additional metabolites were found in the urine.</p><p><em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O‑desmethyl metabolite but the main contributing isoenzyme has not been confirmed<em> in vivo</em>. No clinically relevant difference in lacosamide exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19). Furthermore an interaction trial with omeprazole (CYP2C19‑inhibitor) demonstrated no clinically relevant changes in lacosamide plasma concentrations indicating that the importance of this pathway is minor. The plasma concentration of O‑desmethyl‑lacosamide is approximately 15&nbsp;% of the concentration of lacosamide in plasma. This major metabolite has no known pharmacological activity.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Lacosamide is primarily eliminated from the systemic circulation by renal excretion and biotransformation. After oral and intravenous administration of radiolabeled lacosamide, approximately 95&nbsp;% of radioactivity administered was recovered in the urine and less than 0.5&nbsp;% in the faeces. The elimination half-life of lacosamide is approximately 13&nbsp;hours. The pharmacokinetics is dose-proportional and constant over time, with low intra- and inter-subject variability. Following twice daily dosing, steady state plasma concentrations are achieved after a 3&nbsp;day period. The plasma concentration increases with an accumulation factor of approximately 2.</p><p><u>&nbsp;</u></p><p>A single loading dose of 200&nbsp;mg approximates steady-state concentrations comparable to 100&nbsp;mg twice daily oral administration.</p><p><u>&nbsp;</u></p><p><u>Pharmacokinetics in special patient groups</u></p><p>&nbsp;</p><p><em>Gender</em></p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of lacosamide.</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>The AUC of lacosamide was increased by approximately 30&nbsp;% in mildly and moderately and 60&nbsp;% in severely renal impaired patients and patients with end-stage renal disease requiring haemodialysis compared to healthy subjects, whereas C<sub>max</sub> was unaffected.</p><p>Lacosamide is effectively removed from plasma by haemodialysis. Following a 4‑hour haemodialysis treatment, AUC of lacosamide is reduced by approximately 50&nbsp;%. Therefore, dosage supplementation following haemodialysis is recommended (see section 4.2). The exposure of the O‑desmethyl metabolite was several-fold increased in patients with moderate and severe renal impairment. In absence of haemodialysis in patients with end-stage renal disease, the levels were increased and continuously rising during the 24‑hour sampling. It is unknown whether the increased metabolite exposure in end-stage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has been identified.</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>Subjects with moderate hepatic impairment (Child-Pugh B) showed higher plasma concentrations of lacosamide (approximately 50&nbsp;% higher AUC<sub>norm</sub>). The higher exposure was partly due to a reduced renal function in the studied subjects. The decrease in non-renal clearance in the patients of the study was estimated to give a 20&nbsp;% increase in the AUC of lacosamide. The pharmacokinetics of lacosamide has not been evaluated in severe hepatic impairment (see section 4.2).</p><p><u>&nbsp;</u></p><p><em>Elderly (over 65&nbsp;years of age)</em></p><p>In a study in elderly men and women including 4&nbsp;patients &gt;&nbsp;75&nbsp;years of age, AUC was about 30 and 50&nbsp;% increased compared to young men, respectively. This is partly related to lower body weight. The body weight normalized difference is 26 and 23&nbsp;%, respectively. An increased variability in exposure was also observed. The renal clearance of lacosamide was only slightly reduced in elderly subjects in this study.</p><p>A general dose reduction is not considered to be necessary unless indicated due to reduced renal function (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><em>Paediatric population</em></p><p>The paediatric pharmacokinetic profile of lacosamide was determined in a population pharmacokinetic analysis using sparse plasma concentration data obtained in one placebo-controlled randomised study and three open-label studies in 414&nbsp;children with epilepsy aged 6&nbsp;months to 17&nbsp;years. The administered lacosamide doses ranged from 2 to 17.8&nbsp;mg/kg/day in twice daily intake, with a maximum of 600&nbsp;mg/day for children weighing 50&nbsp;kg or more.</p><p>The typical plasma clearance was estimated to be 1.04&nbsp;L/h, 1.32&nbsp;L/h and 1.86&nbsp;L/h for children weighing 20&nbsp;kg, 30&nbsp;kg and 50&nbsp;kg respectively. In comparison, plasma clearance was estimated at 1.92&nbsp;L/h in adults (70&nbsp;kg body weight).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</strong></p><p>&nbsp;</p><p>In the toxicity studies, the plasma concentrations of lacosamide obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure.</p><p>A safety pharmacology study with intravenous administration of lacosamide in anesthetised dogs showed transient increases in PR interval and QRS complex duration and decreases in blood pressure most likely due to a cardiodepressant action. These transient changes started in the same concentration range as after maximum recommended clinical dosing. In anesthetised dogs and Cynomolgus monkeys, at intravenous doses of 15-60&nbsp;mg/kg, slowing of atrial and ventricular conductivity, atrioventricular block and atrioventricular dissociation were seen.</p><p>In the repeated dose toxicity studies, mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure. These changes included an increased organ weight, hypertrophy of hepatocytes, increases in serum concentrations of liver enzymes and increases in total cholesterol and triglycerides. Apart from the hypertrophy of hepatocytes, no other histopathologic changes were observed.</p><p>In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure. Since higher exposure levels could not be tested in animals due to maternal toxicity, data are insufficient to fully characterise the embryofetotoxic and teratogenic potential of lacosamide.</p><p>Studies in rats revealed that lacosamide and/or its metabolites readily crossed the placental barrier.</p><p>In juvenile rats and dogs, the types of toxicity do not differ qualitatively from those observed in adult animals. In juvenile rats, a reduced body weight was observed at systemic exposure levels similar to the expected clinical exposure. In juvenile dogs, transient and dose-related CNS clinical signs started to be observed at systemic exposure levels below the expected clinical exposure.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p>water for injections</p><p>sodium chloride</p><p>hydrochloric acid (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</strong></p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3	Shelf life

3 years.

Chemical and physical in-use stability has been demonstrated for 24 hours at temperatures up to 25°C for product mixed with the diluents mentioned in 6.6 and stored in glass or PVC bags.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for storage</strong></p><p>&nbsp;</p><p>Do not store above 25&deg;C.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of container</strong></p><p>&nbsp;</p><p>Colourless type I glass vial with a chlorobutyl rubber closure coated with a fluoropolymer.<br />Packs of 1x20&nbsp;ml and 5x20&nbsp;ml.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for disposal and other handling</strong></p><p>&nbsp;</p><p>Product with particulate matter or discolouration should not be used.</p><p>This medicinal product is for single use only, any unused solution should be discarded.</p><p>Vimpat solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24&nbsp;hours and stored in glass or PVC bags at temperatures up to 25&deg;C.</p><p>Diluents:</p><p>sodium chloride 9&nbsp;mg/ml (0.9&nbsp;%) solution for injection</p><p>glucose 50&nbsp;mg/ml (5&nbsp;%) solution for injection</p><p>lactated Ringer&rsquo;s solution for injection.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                UCB Pharma S.A.
Allée de la Recherche 60
B 1070 Bruxelles
Belgium



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of first authorisation: 29 August 2008
Date of latest renewal: 31 July 2013

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>